166 related articles for article (PubMed ID: 38546962)
1. Human Medicines Recall Announcements in Saudi Arabia Between 2017 and 2022: An Analysis of Saudi Food and Drug Authority (SFDA) Reports.
Almutairi M; Algabbani A; Alasiri A; Alhomaidan A; Alqahtani AS
Ther Innov Regul Sci; 2024 Jul; 58(4):689-695. PubMed ID: 38546962
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of FDA drug recalls: A 30-month analysis.
Hall K; Stewart T; Chang J; Freeman MK
Am J Health Syst Pharm; 2016 Feb; 73(4):235-40. PubMed ID: 26843501
[TBL] [Abstract][Full Text] [Related]
3. Local causes of essential medicines shortages from the perspective of supply chain professionals in Saudi Arabia.
AlRuthia Y; Mohammed Almutiri N; Musa Almutairi R; Almohammed O; Alhamdan H; Ali El-Haddad S; Abdu Asiri Y
Saudi Pharm J; 2023 Jun; 31(6):948-954. PubMed ID: 37234344
[TBL] [Abstract][Full Text] [Related]
4. A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023.
Patel R; Vhora A; Jain D; Patel R; Khunt D; Patel R; Dyawanapelly S; Junnuthula V
Drug Discov Today; 2024 Jun; 29(6):103993. PubMed ID: 38670257
[TBL] [Abstract][Full Text] [Related]
5. Categorization and comparisons of drug recalls for manufacturers and compounders.
Mattingly AN; Mattingly TJ; Nguyen Phan AL; Negash K
J Am Pharm Assoc (2003); 2022; 62(4):1344-1350. PubMed ID: 35422393
[TBL] [Abstract][Full Text] [Related]
6. Drug and medical device product failures and the stability of the pharmaceutical supply chain.
Livingston AN; Mattingly TJ
J Am Pharm Assoc (2003); 2021; 61(1):e119-e122. PubMed ID: 32753251
[TBL] [Abstract][Full Text] [Related]
7. Moulds associated with contaminated ocular and injectable drugs: FDA recalls, epidemiology considerations, drug shortages, and aseptic processing.
Ahearn DG; Stulting RD
Med Mycol; 2018 Jun; 56(4):389-394. PubMed ID: 29420758
[TBL] [Abstract][Full Text] [Related]
8. Quality of Medicines in Portugal: A Retrospective Review of Medicine Recalls (2000-2015).
Machado Reis AT; Berardo BFR; Loureiro R
PDA J Pharm Sci Technol; 2018; 72(1):44-49. PubMed ID: 29030530
[TBL] [Abstract][Full Text] [Related]
9. Review of drug recalls and quality of pharmaceutical products in Nepal.
Neupane A; Bastakoti M; Tamang S; Giri B
BMJ Open; 2022 Jul; 12(7):e053479. PubMed ID: 35788073
[TBL] [Abstract][Full Text] [Related]
10. Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems.
Chabalenge B; Jere E; Nanyangwe N; Hikaambo C; Mudenda S; Banda M; Kalungia A; Matafwali S
J Med Access; 2022; 6():27550834221141767. PubMed ID: 36601496
[TBL] [Abstract][Full Text] [Related]
11. Quality of medicines in Canada: a retrospective review of risk communication documents (2005-2013).
Almuzaini T; Sammons H; Choonara I
BMJ Open; 2014 Oct; 4(10):e006088. PubMed ID: 25361839
[TBL] [Abstract][Full Text] [Related]
12. A four-year assessment of the characteristics of Rwandan FDA drug recalls.
Bahizi M; Nyirimigabo E; Ntirenganya L; Umuhoza MI; Habyalimana V; Bikorimana G; Ukwishaka J
BMC Public Health; 2024 Jul; 24(1):1784. PubMed ID: 38965502
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical Pricing Policies and Procedures in Saudi Arabia: A Narrative Review.
Khan TM; Emeka P; Suleiman AK; Alnutafy FS; Aljadhey H
Ther Innov Regul Sci; 2016 Mar; 50(2):236-240. PubMed ID: 30227009
[TBL] [Abstract][Full Text] [Related]
14. Readability of information imprinted in patient information leaflets (PILs) in Saudi Arabia: The case of antihypertensive medications.
Algabbani AM; Alzahrani SA; Almomen SM; Hafiz RA
Explor Res Clin Soc Pharm; 2022 Dec; 8():100179. PubMed ID: 36177271
[TBL] [Abstract][Full Text] [Related]
15. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
16. Twenty-Two Years of U.S. Meat and Poultry Product Recalls: Implications for Food Safety and Food Waste.
Gorton A; Stasiewicz MJ
J Food Prot; 2017 Apr; 80(4):674-684. PubMed ID: 28294687
[TBL] [Abstract][Full Text] [Related]
17. The Identification of Quality Risk Factors for Non-biological Complex Drugs and Epilepsy Drugs Using Statistical Analysis of Formulation-Based Recalls in the USA.
Kerstiens EA; Byrn SR; Clase KL
AAPS PharmSciTech; 2021 Dec; 23(1):19. PubMed ID: 34904204
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence trials for the approval of generic drugs in Saudi Arabia: a descriptive analysis of design aspects.
Althunian TA; Alzenaidy BR; Alroba RA; Almadani OA; Alqahtani FA; Binajlan AA; Almousa AI; Alamr DK; Al-Mofada MS; Alsaqer NY; Alarfaj HA; Bahlewa AA; Alharbi MA; Alhomaidan AM; Alsuwyeh AA; Alsaleh AA
BMC Med Res Methodol; 2024 Apr; 24(1):82. PubMed ID: 38580928
[TBL] [Abstract][Full Text] [Related]
19. A cross-sectional study of prevalence, distribution, cause, and impact of blood product recalls in the United States.
Alqemlas I; Shankar S; Handagama W; Felse PA
Blood Adv; 2020 Apr; 4(8):1780-1791. PubMed ID: 32343797
[TBL] [Abstract][Full Text] [Related]
20. [Trends in Non-prescription Drug Recalls in Japan].
Yamamoto C; Ishida T; Osawa T; Naito T; Kawakami J
Yakugaku Zasshi; 2016; 136(9):1307-12. PubMed ID: 27592833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
